Virology & Parasitology Osaka Metropolitan University

Mpox research initiative

Japan · Osaka Metropolitan University DR Congo · INRB Belgium · Institute of Tropical Medicine, Antwerp

Mpox research spanning genomics, serology and pathology

Tracking mpox virus evolution and immune cross-protection, from Kinshasa to Osaka.

Period
2022 — ongoing
Clades
Ia · Ib · IIa · IIb
Funding
AMED · FY2022–2023 supplementary call

The question

Why mpox, now?

The mpox virus (MPXV) triggered successive Public Health Emergencies of International Concern (PHEIC) — clade IIb in 2022 and clade Ib in 2024. New variants keep emerging at a pace unusual for a DNA virus, yet the immunological evidence for how far past infection or vaccination cross-protects remains insufficient.

In the sequela cohort we follow in DR Congo, patients believed cured have shown lasting cases of social blindness from corneal opacity and peripheral neuropathy. With risks of immune-escape and highly pathogenic strains emerging, reading the contest between virus and immunity across genomics, serology and pathology is now required.

Partner institutions

Japan — Belgium — DR Congo

A three-country collaboration circulating specimens, data and findings.

01 Japan

Osaka Metropolitan University

Graduate School of Medicine

Serology platform development · integrated analysis

Developing whole-antigen bead assays and protein arrays, and integrating specimen data across the international cohort.

Research team

Ishikane, Adachi, Nakamura, Kaku, Yasuki

02 DR Congo

INRB

Institut National de Recherche Biomédicale

Case cohort · sequela follow-up

Tracking confirmed cases from Kinshasa, providing clade Ia specimens and one year of sequela data.

INRB, DR Congo

Dr. Placide Mbala

03 Belgium

Institute of Tropical Medicine, Antwerp

Institute of Tropical Medicine, Antwerp

Method validation in an international cohort

Validating the serodiagnostic algorithm with European clade IIb specimens and analyzing regional differences.

Institute of Tropical Medicine, Antwerp

Dr. Laurens Liesenborghs

Specimens and data circulate across the three countries to continuously validate and refine the serodiagnostic algorithm. The network runs on three axes: joint research and publication, and young-researcher exchange.

Approach

Layering genomics, serology and pathology on a single specimen.

We render the whole picture of mpox — which no single method can capture — from four layers.

Layer 01

Genomics

ゲノミクス

Using de novo assembly to determine full-length genomes including the hard-to-reconstruct ends, comparing insertions, deletions and repeats between strains to trace clues to transmission.

Layer 02

Epidemiology

疫学

Tracing the relationship between genotype and transmission pattern, and drawing the clinical picture through a one-year post-recovery sequela cohort.

Wawina-Bokalanga et al., Lancet 2025;406:63–75

Layer 03

Serology

血清学

Using whole-antigen bead assays and comprehensive protein arrays to elucidate antigen patterns reflecting neutralizing activity and cross-immunity between infection and vaccination.

Viruses 2023;15(4):995 · BMC Infect Dis 2025;25:529

Layer 04

Pathology

病理学

Infecting 3D skin-mimicking cultures with the virus to observe tissue disruption and replication dynamics, feeding into future drug-discovery and immunology platforms.

Viruses 2023;15(8):1748

Sub-topics

Entry points

Expanding into five themes.

01

Genomics

MPXV whole-genome analysis and phylogenetic surveillance through strain comparison

Coming soon
02

Epidemiology & natural history

Elucidating transmission dynamics and one-year post-recovery sequela follow-up

Coming soon
03

Seroepidemiology

Elucidating cross-immunity via whole-antigen assays and AMED-supported platform development

Coming soon
04

Pathology

3D culture skin models and analysis of viral replication dynamics

Coming soon
05

POCT development

Field-ready rapid diagnostics using LAMP

Coming soon